Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$7.90 CAD
Change Today -0.40 / -4.82%
Volume 57.3K
RX On Other Exchanges
Symbol
Exchange
OTC US
Venture
As of 3:59 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for biosyent inc (RX)

BioSyent Inc. has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total C$7.0M CAD. Accounts Receivable are among the industry's worst with 17.94 days worth of sales outstanding. This implies that revenues are not being collected in an efficient manner. Last, inventory levels, relative to its Cost of Goods Sold, are typical for the industry and have shown a consistent decrease during the last 4 years. This implies that management is becoming more efficient.
View Balance Sheet In U.S. Dollar
Currency in
Millions of Canadian Dollars
As of:Dec 31
2011
Restated
CAD
Dec 31
2012
CAD
Dec 31
2013
Restated
CAD
Dec 31
2014
CAD
4 Year
Trend
Assets    
Cash and Equivalents1.12.34.47.0
Short-Term Investments------1.0
TOTAL CASH AND SHORT TERM INVESTMENTS1.12.34.48.0
Accounts Receivable0.30.60.60.6
Other Receivables0.00.00.00.0
TOTAL RECEIVABLES0.30.60.60.6
Inventory0.10.30.51.3
Prepaid Expenses0.00.10.10.2
Other Current Assets------0.1
TOTAL CURRENT ASSETS1.63.35.610.2
Gross Property Plant and Equipment0.00.10.10.1
Accumulated Depreciation0.00.00.0-0.1
NET PROPERTY PLANT AND EQUIPMENT0.00.10.10.1
Deferred Tax Assets, Long Term--0.20.30.2
Other Intangibles0.00.00.10.2
TOTAL ASSETS1.63.76.110.6
    
LIABILITIES & EQUITY    
Accounts Payable0.40.70.82.0
Current Income Taxes Payable--0.10.50.5
TOTAL CURRENT LIABILITIES0.40.81.22.5
Deferred Tax Liability Non-Current----0.00.0
TOTAL LIABILITIES0.40.81.22.5
Common Stock6.97.07.17.1
Additional Paid in Capital0.20.20.20.3
Retained Earnings-5.9-4.3-2.40.7
Comprehensive Income and Other0.00.00.00.0
TOTAL COMMON EQUITY1.22.84.98.2
TOTAL EQUITY1.22.84.98.2
TOTAL LIABILITIES AND EQUITY1.63.76.110.6
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RX:CN C$7.90 CAD -0.40

RX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RX.
View Industry Companies
 

Industry Analysis

RX

Industry Average

Valuation RX Industry Range
Price/Earnings 34.4x
Price/Sales 8.3x
Price/Book 12.8x
Price/Cash Flow 33.2x
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSYENT INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.